Hostname: page-component-848d4c4894-m9kch Total loading time: 0 Render date: 2024-05-04T08:15:19.645Z Has data issue: false hasContentIssue false
  • English
  • Français

Using Topiramate in Patients with Epilepsy: Practical Aspects

Published online by Cambridge University Press:  18 September 2015

J.W.A.S. Sander
J.W.A.S. Sander*
Affiliation:
Epilepsy Research Group, Institute of Neurology, National Hospital for Neurology and Neurosurgery, Queen Square, London, United Kingdom
*
Epilepsy Research Group, National Hospital for Neurology and Neurosurgery, 33 Queen Square, London WC1N 3B6, United Kingdom
Rights & Permissions [Opens in a new window]

Abstract:

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Clinical trials are important in determining the relative efficacy and safety of a new antiepileptic drug (AED); however, experience acquired in clinical practice will eventually determine its position in the antiepileptic armamentarium. Topiramate (TPM), a new AED has been available in the United Kingdom since mid-1995 and a considerable number of patients have being treated. As a result of this experience, a number of changes have being made in the way TPM is used, particularly in the starting doses and titration rates. This seems to have improved patients' tolerability of treatment, an important consideration if a drug is to be used to its optimum level. In this article, practical tips for the use of TPM are given and these include starting doses, titration rates, options for managing side effects occurring early in treatment, advice concerning the withdrawal of concomitant AEDs and indications for discontinuation of TPM. The need for adequate patient counseling regarding potential side effects and expectations of treatment is also reviewed.

Type
Research Article
Information
Canadian Journal of Neurological Sciences , Volume 25 , Issue S3 , August 1998 , pp. S16 - S18
Copyright
Copyright © Canadian Neurological Sciences Federation 1998

References

REFERENCES

1.Walker, MC, Sander, JWAS. Difficulties in extrapolating from clinical trial data to clinical practice: the case of antiepileptic drugs. Neurology 1997;49:333–337.CrossRefGoogle ScholarPubMed
2.Walker, MC, Sander, JWAS. The impact of new antiepileptic drugs on the prognosis of epilepsy: seizure freedom should be the ultimate goal. Neurology 1996; 46: 912–914.CrossRefGoogle ScholarPubMed
3.Faught, E, Wilder, BJ, Ramsay, RE, et al. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, and 600-mg daily dosages. Neurology 1996; 46: 1684–1690.CrossRefGoogle ScholarPubMed
4.Privitera, M, Fincham, R, Penry, J, et al. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 600-. 800-, and 1,000-mg daily dosages. Neurology 1996; 46: 1678–1683.CrossRefGoogle ScholarPubMed
5.Ben-Menachem, E, Henriksen, O, Dam, M, et al. Double-blind, placebo-controlled trial of topiramate as add-on therapy in patients with refractory partial seizures. Epilepsia 1996; 37: 539–543.CrossRefGoogle ScholarPubMed
6.Sachdeo, R, Reife, R, Lim, P, Pledger, G. Single-center topiramate monotherapy trial. Epilepsia 1995; 36 (Suppl 3): 151.Google Scholar
7.Biton, V. Preliminary open-label experience with topiramate in primary generalized seizures. Epilepsia 1997; 38(Suppl 1): S42-S45.CrossRefGoogle ScholarPubMed
8.Espe-Lillo, J, Ritter, FJ, Frost, MD, Spiegel, RH, Reife, R. Topiramate in childhood epilepsy: titration, adverse events, and efficacy in multiple seizure types. Epilepsia 1995; 36 (Suppl 4): 56.Google Scholar
9.Shorvon, S. Safety of topiramate: adverse events and relationships to dosing. Epilepsia 1996; 37 (Suppl 2): 18–22.CrossRefGoogle ScholarPubMed
10.Bourgeois BFD. Drug interaction profile of topiramate. Epilepsia 1996; 37 (Suppl 2): 14–17.Google Scholar
11.Walker, MC, Sander, JWAS. Topiramate: a new antiepileptic drug for refractory epilepsy. Seizure 1996; 5: 199–203.CrossRefGoogle ScholarPubMed